Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05160389 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200

A Phase 1 study of Food Effect in Healthy Volunteers, sponsored by Pyramid Biosciences.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT05160389: Completed Phase 1 study of Food Effect in Healthy Volunteers, sponsored by Pyramid Biosciences.

NCT05160389 is a Phase 1 study of Food Effect in Healthy Volunteers that has completed, run by Pyramid Biosciences. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05160389, a Phase 1 study of Food Effect in Healthy Volunteers, has completed, sponsored by Pyramid Biosciences.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

This is a single-dose, open-label, randomized, three-way crossover study to assess the effect of food on the absorption and bioavailability of PBI-200.

Primary Outcome

Tmax will be determined from the observed plasma concentration data.

Interventions

  • DRUG PBI-200

Study Locations (1)

Missouri

  • Bio-Kinetic Clinical Applications - Springfield

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2021-11-17
Est. Completion 2022-01-06
Phase Phase 1
Pyramid Biosciences

7 total trials

What the finished NCT05160389 record still lists

NCT05160389 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).

The record links to 1 condition, with Food Effect in Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which PBI-200 is the first listed.

NCT05160389 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT05160389 about?

NCT05160389 is a clinical study titled "A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200". This is a single-dose, open-label, randomized, three-way crossover study to assess the effect of food on the absorption and bioavailability of PBI-200.

What is the current status of trial NCT05160389?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2021-11-17. Estimated completion is 2022-01-06.

What conditions does trial NCT05160389 study?

This clinical trial studies the following conditions: Food Effect in Healthy Volunteers.

What interventions are being tested in trial NCT05160389?

The interventions under investigation include: PBI-200 (DRUG).

Who is sponsoring clinical trial NCT05160389?

This trial is sponsored by Pyramid Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05160389 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT05160389's enrollment target sits among peer trials

16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05160389, the US trial registry maintained by the National Library of Medicine. NCT05160389 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.